Cancer of Unknown Primary Site in which Tumor Marker-Oriented Chemotherapy was Effective and Pancreatic Cancer was Finally Confirmed at Autopsy

被引：1

作者：

Ohtsubo, Koushiro ^{[1
]}

Watanabe, Hiroyuki ^{[1
]}

Yamada, Tadaaki ^{[1
]}

Tsuchiyama, Tomoya ^{[1
]}

Mouri, Hisatsugu ^{[1
]}

Yamashita, Kaname ^{[2
]}

Yasumoto, Kazuo ^{[2
]}

Ikeda, Hiroko ^{[3
]}

Nakanuma, Yasuni ^{[3
]}

Yano, Seiji ^{[1
]}

机构：

[1] Kanazawa Univ, Canc Res Inst, Div Med Oncol, Kanazawa, Ishikawa 920, Japan

[2] Kanazawa Univ, Canc Res Inst, Div Surg Oncol, Kanazawa, Ishikawa 920, Japan

[3] Kanazawa Univ, Dept Human Pathol, Kanazawa, Ishikawa 920, Japan

来源：

INTERNAL MEDICINE | 2009年 / 48卷 / 18期

关键词：

cancer of unknown primary site; pancreatic cancer; tumor marker; immunohistochemistry; chemotherapy; RANDOMIZED PHASE-III; PLUS CISPLATIN; GEMCITABINE; CARCINOMA; TRIAL; ADENOCARCINOMA; COMBINATION; CARBOPLATIN; PACLITAXEL; SURVIVAL;

D O I：

10.2169/internalmedicine.48.2432

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We report a 47-year-old man with cancer of unknown primary site in whom pancreatic cancer was confirmed at autopsy. Although a primary lesion was not confirmed, we planned to perform turner marker-oriented chemotherapy because pancreatic cancer was suspected as the primary lesion based on tumor markers and pathological findings from metastatic lymph node. Neither S-1 nor gemcitabine was effective. However, gemcitabine combined with low-dose cisplatin therapy resulted in a marked decrease in the size of tumors, Microscopic examination at autopsy revealed poorly differentiated adenocarcinoma in the pancreatic head, although a pancreatic mass was not clear macroscopically.

引用

页码：1651 / 1656

页数：6

共 24 条

[1] [Anonymous], NCCN PRACT GUID ONC
[2] Management of cancer from an unknown primary
Armstrong, Anne C.
Blackhall, Fiona H.
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (04) : 445 - 455
[3] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
Burris, HA
Moore, MJ
Andersen, J
Green, MR
Rothenberg, ML
Madiano, MR
Cripps, MC
Portenoy, RK
Storniolo, AM
Tarassoff, P
Nelson, R
Dorr, FA
Stephens, CD
VanHoff, DD
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2403 - 2413
[4] PHASE-II TRIAL OF GEMCITABINE (2,2'-DIFLUORODEOXYCYTIDINE) IN PATIENTS WITH ADENOCARCINOMA OF THE PANCREAS
CASPER, ES
GREEN, MR
KELSEN, DP
HEELAN, RT
BROWN, TD
FLOMBAUM, CD
TROCHANOWSKI, B
TARASSOFF, PG
[J]. INVESTIGATIONAL NEW DRUGS, 1994, 12 (01) : 29 - 34
[5] Colucci G, 2002, CANCER, V94, P902, DOI 10.1002/cncr.10323.abs
[6] DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin
Crul, M
van Waardenburg, RCAM
Bocxe, S
van Eijndhoven, MAJ
Pluim, D
Beijnen, JH
Schellens, JHM
[J]. BIOCHEMICAL PHARMACOLOGY, 2003, 65 (02) : 275 - 282
[7] Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site:: Results of a randomized phase II study-trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)
Culine, S
Lortholary, A
Voigt, JJ
Bugat, R
Théodore, C
Priou, F
Kaminsky, MC
Lesimple, T
Pivot, X
Coudert, B
Douillar, JY
Merrouche, Y
Allouache, J
Goupil, A
Négrier, S
Viala, J
Petrow, P
Bouzy, J
Laplanche, A
Fizazi, K
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) : 3479 - 3482
[8] Treatment of patients with specific subsets of carcinoma of an unknown primary site
Fizazi, K.
[J]. ANNALS OF ONCOLOGY, 2006, 17 : X177 - X180
[9] Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin
Greco, FA
Erland, JB
Morrissey, LH
Burris III, HA
Hermann, RC
Steis, R
Thompson, D
Gray, J
Hainsworth, JD
[J]. ANNALS OF ONCOLOGY, 2000, 11 (02) : 211 - 215
[10] Greco FA, 2000, CANCER, V89, P2655, DOI 10.1002/1097-0142(20001215)89:12<2655::AID-CNCR19>3.3.CO

← 1 2 3 →